Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871633]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7181003]
第一作者单位：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
通讯作者：
通讯机构：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China[*1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
推荐引用方式(GB/T 7714)：
Meng Guang-Qiang,Wang Yi-Ni,Wang Jing-Shi,et al.Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis[J].CHINESE MEDICAL JOURNAL.2021,134(13):1624-1625.doi:10.1097/CM9.0000000000001324.
APA：
Meng Guang-Qiang,Wang Yi-Ni,Wang Jing-Shi&Wang Zhao.(2021).Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.CHINESE MEDICAL JOURNAL,134,(13)
MLA：
Meng Guang-Qiang,et al."Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis".CHINESE MEDICAL JOURNAL 134..13(2021):1624-1625
